We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Treatment Modalities for Non-Muscle Invasive Bladder Cancer: An Updated Review.
- Authors
McNall, Shannon; Hooper, Kailey; Sullivan, Travis; Rieger-Christ, Kimberly; Clements, Matthew
- Abstract
Simple Summary: The mainstay of treatment for non-muscle invasive bladder cancer is transurethral resection of the tumor followed by intravesical treatment for intermediate- or high-risk disease. Duration and type of intravesical treatment depend on specific characteristics of the tumor and the patient's disease course. Patients with non-muscle invasive bladder cancer are closely monitored with frequent surveillance cystoscopies following treatment. This type of cancer has a low progression rate; however, it has a high rate of recurrence with the current recommended treatments. Therefore, patients often find themselves having to undergo multiple resections and rounds of intravesical treatment throughout their lifetime. This is not only burdensome for patients but also costly for the healthcare system. Given the high recurrence with the standard treatment options, it is important to continue investigating novel therapies. The goal of this review article is to outline the most recent therapies available or in clinical trials for the treatment of non-muscle invasive bladder cancer. The landscape of treatment for non-muscle invasive bladder cancer is rapidly changing. A complete and careful transurethral resection is the mainstay of initial treatment and is followed by intravesical therapy in intermediate or high-risk cases. The standard of care is intravesical BCG. Many alternative or additive approaches to this are being explored. We divided this review into three relevant spaces to consider these novel treatment approaches: (1) low-risk disease, for which intravesical therapy is not usually considered, (2) BCG-naïve disease (i.e., considering alternatives to the standard therapy), and (3) BCG-unresponsive disease. We performed a review of published literature and summarized ongoing trials in the United States. Novel approaches that we explored include surgical techniques for resection, alterations in dwell time for intravesical therapy, delivery method and schedule of intravesical therapies, new intravesical therapy agents, and systemic therapies (especially immunotherapy). These are thoroughly outlined throughout this review article, and the numerous modalities being studied demonstrate significant promise for the future treatment of the expanding space of NMIBC.
- Subjects
UNITED States; THERAPEUTIC use of antineoplastic agents; NON-muscle invasive bladder cancer; INTRAVESICAL administration; BCG vaccines; IMMUNOTHERAPY; TRANSURETHRAL resection of bladder; DISEASE risk factors
- Publication
Cancers, 2024, Vol 16, Issue 10, p1843
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers16101843